252 related articles for article (PubMed ID: 19255346)
1. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms.
Lombardi R; Rodriguez G; Chen SN; Ripplinger CM; Li W; Chen J; Willerson JT; Betocchi S; Wickline SA; Efimov IR; Marian AJ
Circulation; 2009 Mar; 119(10):1398-407. PubMed ID: 19255346
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Senthil V; Chen SN; Tsybouleva N; Halder T; Nagueh SF; Willerson JT; Roberts R; Marian AJ
Circ Res; 2005 Aug; 97(3):285-92. PubMed ID: 16020756
[TBL] [Abstract][Full Text] [Related]
3. Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): A Randomized, Placebo-Controlled, Double-Blind Pilot Study.
Marian AJ; Tan Y; Li L; Chang J; Syrris P; Hessabi M; Rahbar MH; Willerson JT; Cheong BY; Liu CY; Kleiman NS; Bluemke DA; Nagueh SF
Circ Res; 2018 Apr; 122(8):1109-1118. PubMed ID: 29540445
[TBL] [Abstract][Full Text] [Related]
4. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy.
Nagueh SF; Chen S; Patel R; Tsybouleva N; Lutucuta S; Kopelen HA; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
J Mol Cell Cardiol; 2004 May; 36(5):663-73. PubMed ID: 15135661
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Patel R; Nagueh SF; Tsybouleva N; Abdellatif M; Lutucuta S; Kopelen HA; Quinones MA; Zoghbi WA; Entman ML; Roberts R; Marian AJ
Circulation; 2001 Jul; 104(3):317-24. PubMed ID: 11457751
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation.
Marian AJ; Senthil V; Chen SN; Lombardi R
J Am Coll Cardiol; 2006 Feb; 47(4):827-34. PubMed ID: 16487852
[TBL] [Abstract][Full Text] [Related]
7. Experimental therapies in hypertrophic cardiomyopathy.
Marian AJ
J Cardiovasc Transl Res; 2009 Dec; 2(4):483-92. PubMed ID: 20560006
[TBL] [Abstract][Full Text] [Related]
8. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Nagueh SF; Kopelen HA; Lim DS; Zoghbi WA; Quiñones MA; Roberts R; Marian AJ
Circulation; 2000 Sep; 102(12):1346-50. PubMed ID: 10993850
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Tsybouleva N; Zhang L; Chen S; Patel R; Lutucuta S; Nemoto S; DeFreitas G; Entman M; Carabello BA; Roberts R; Marian AJ
Circulation; 2004 Mar; 109(10):1284-91. PubMed ID: 14993121
[TBL] [Abstract][Full Text] [Related]
11. Blocking cardiac growth in hypertrophic cardiomyopathy induces cardiac dysfunction and decreased survival only in males.
Luckey SW; Mansoori J; Fair K; Antos CL; Olson EN; Leinwand LA
Am J Physiol Heart Circ Physiol; 2007 Feb; 292(2):H838-45. PubMed ID: 17012357
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of hypertrophic cardiomyopathy caused by myozenin 2 mutations is independent of calcineurin activity.
Ruggiero A; Chen SN; Lombardi R; Rodriguez G; Marian AJ
Cardiovasc Res; 2013 Jan; 97(1):44-54. PubMed ID: 22987565
[TBL] [Abstract][Full Text] [Related]
13. A Murine Hypertrophic Cardiomyopathy Model: The DBA/2J Strain.
Zhao W; Zhao T; Chen Y; Zhao F; Gu Q; Williams RW; Bhattacharya SK; Lu L; Sun Y
PLoS One; 2015; 10(8):e0133132. PubMed ID: 26241864
[TBL] [Abstract][Full Text] [Related]
14. N-Acetylcysteine Influence on Oxidative Stress and Cardiac Remodeling in Rats During Transition from Compensated Left Ventricular Hypertrophy to Heart Failure.
Reyes DRA; Gomes MJ; Rosa CM; Pagan LU; Damatto FC; Damatto RL; Depra I; Campos DHS; Fernandez AAH; Martinez PF; Okoshi K; Okoshi MP
Cell Physiol Biochem; 2017; 44(6):2310-2321. PubMed ID: 29258061
[TBL] [Abstract][Full Text] [Related]
15. A transgenic rabbit model for human hypertrophic cardiomyopathy.
Marian AJ; Wu Y; Lim DS; McCluggage M; Youker K; Yu QT; Brugada R; DeMayo F; Quinones M; Roberts R
J Clin Invest; 1999 Dec; 104(12):1683-92. PubMed ID: 10606622
[TBL] [Abstract][Full Text] [Related]
16. An insight of novel pharmacological therapies in hypertrophic cardiomyopathy.
Orenes-Piñero E; Hernández-Romero D; Jover E; de la Morena G; Valdés M; Marín F
Med Chem; 2011 Jul; 7(4):275-85. PubMed ID: 21568880
[TBL] [Abstract][Full Text] [Related]
17. Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
Kuster DWD; Lynch TL; Barefield DY; Sivaguru M; Kuffel G; Zilliox MJ; Lee KH; Craig R; Namakkal-Soorappan R; Sadayappan S
Cardiovasc Res; 2019 Dec; 115(14):1986-1997. PubMed ID: 31050699
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.
Wilder T; Ryba DM; Wieczorek DF; Wolska BM; Solaro RJ
Am J Physiol Heart Circ Physiol; 2015 Nov; 309(10):H1720-30. PubMed ID: 26432840
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy.
Ryba DM; Warren CM; Karam CN; Davis RT; Chowdhury SAK; Alvarez MG; McCann M; Liew CW; Wieczorek DF; Varga P; Solaro RJ; Wolska BM
Circ Heart Fail; 2019 Nov; 12(11):e005835. PubMed ID: 31684756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
